Anti Epcam Aptamer (Syl3c) Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma
In this study, we have surface functionalized PEGylated nanoliposomal doxorubicin (DOX) with anti EpCAM (epithelial cell adhesion molecule) aptamer via post insertion of anti EpCAM aptamer conjugated DSPE mPEG 2000 into Caelyx(r) (ED lip) The size, charge, release profile, and cytotoxicity and cellular uptake of formulation were determined. The characterization of the ED lip demonstrated the slightly increase in size and PDI along with the decrease in zeta potential which indicated that post insertion efficiently done. The results of flow cytometry and fluorescent microscopy have shown that ED lip enhanced the rate of cell uptake on C26 cell line compared to Caelyx(r) The ED lip also had more cytotoxic effects than Caelyx(r) which indicated the efficacy of anti EpCAM aptamer as targeting ligand. The pharmacokinetic and tissue biodistribution of formulations in mice bearing C26 tumors demonstrated that ED lip did not affect the distribution profile of DOX compared to Caelyx(r) in animal model. In addition, ED lip effectively improved the tumor accumulation of DOX and promoted survival of animals compared to Caelyx(r) These results suggest that the functionalization of Caelyx(r) with anti EpCAM aptamer is promising in cancer treatment and merits further investigation.
Nanoscale Research Letters